Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

S&P Industrial Sector Intl SPDR (IPN)

S&P Industrial Sector Intl SPDR (IPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family N/A
  • Assets Under Management 0
  • Shares Outstanding, K 500
  • 60-Month Beta 0.96
Trade IPN with:
  • Price/Earnings ttm N/A
  • Annual Dividend & Yield 0.58 (1.66%)
  • Most Recent Dividend N/A on N/A
  • Management Fee N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.13 +1.70%
on 07/06/17
35.31 -1.70%
on 07/13/17
-0.11 (-0.32%)
since 06/23/17
3-Month
33.44 +3.80%
on 04/26/17
35.38 -1.89%
on 06/14/17
+1.38 (+4.14%)
since 04/24/17
52-Week
28.70 +20.94%
on 07/25/16
35.38 -1.89%
on 06/14/17
+6.02 (+20.98%)
since 07/22/16

Most Recent Stories

More News
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvayâ„¢ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

/CNW/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and...

IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.

Regulatory News:

OTC.VN : 0.340 (+9.68%)
IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI

Regulatory News:

OTC.VN : 0.340 (+9.68%)
IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

Regulatory News:

OTC.VN : 0.340 (+9.68%)
ALBO : 44.15 (-0.23%)
IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

Regulatory News:

OTC.VN : 0.340 (+9.68%)
IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy

Regulatory News:

OTC.VN : 0.340 (+9.68%)
IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Regulatory News:

OTC.VN : 0.340 (+9.68%)
IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance

Regulatory News:

OTC.VN : 0.340 (+9.68%)
IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting

Regulatory News:

OTC.VN : 0.340 (+9.68%)
IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology

Regulatory News:

OTC.VN : 0.340 (+9.68%)
IPN : 34.71 (-0.54%)
IPSEY : 28.7550 (+0.12%)

Fund Summary

N/A

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 34.84
1st Resistance Point 34.77
Last Price 34.71
1st Support Level 34.58
2nd Support Level 34.46
3rd Support Level N/A

See More

52-Week High 35.38
Last Price 34.71
Fibonacci 61.8% 32.83
Fibonacci 50% 32.04
Fibonacci 38.2% 31.25
52-Week Low 28.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar